Welcome to our dedicated page for Callan JMB news (Ticker: CJMB), a resource for investors and traders seeking the latest updates and insights on Callan JMB stock.
Callan JMB Inc. (NASDAQ: CJMB) is an integrative logistics company focused on highly regulated, temperature‑sensitive supply chains for healthcare, pharmaceuticals, and emergency preparedness. This news page aggregates company‑specific announcements, business updates, and regulatory disclosures so readers can follow how Callan JMB’s logistics, cold chain, and monitoring capabilities evolve over time.
Recent news highlights include strategic agreements and growth initiatives that shape the company’s role in integrated freight and logistics. Callan JMB has reported a strategic teaming agreement with Biostax Corp d/b/a Attune Biotech Inc., under which it will act as an independent third‑party overseer for manufacturing quality assurance, BARDA contract compliance, FDA audit readiness, federal reporting, and Strategic National Stockpile deployment coordination for Attune’s therapeutic pipeline. The company has also announced a strategic realignment toward cold‑chain infrastructure for GLP‑1 medications, including retrofitting its Texas cGMP facility for high‑capacity pharmaceutical‑grade refrigeration and positioning its cold‑chain technology for last‑mile fulfillment.
Other news items cover expansion into the food sampling sector, the launch of a subsidiary in India to establish a temperature‑controlled pharmaceutical warehouse, and upgrades to the proprietary Sentry Monitoring System to version 4.0, enabling web‑based access to temperature data and alarms from any device. Financial results releases provide context on revenue trends, contract extensions such as the long‑term City of Chicago emergency preparedness agreement, and capital markets activities including equity line arrangements.
Investors, analysts, and industry observers can use this page to review Callan JMB’s earnings releases, partnership announcements, technology upgrades, conference participation, and government contract updates, all in one place. Bookmark this feed to quickly access the latest CJMB news as reported in company press releases and SEC‑related communications.
Callan JMB (NASDAQ: CJMB) announced that underwriters have partially exercised their over-allotment option from its initial public offering, issuing an additional 163,569 shares at $4.00 per share, generating additional gross proceeds of $654,276.
Following this partial exercise, the total IPO has reached 1,443,569 shares with aggregate net proceeds of approximately $4.73 million after deducting underwriting discounts, commissions, and offering expenses. Alexander Capital served as the managing underwriter and sole book runner, with Paulson Investment Company and Bancroft Capital as co-managers.
Callan JMB (NASDAQ: CJMB) has successfully completed its initial public offering (IPO), raising approximately $5.12 million in gross proceeds through the sale of 1,280,000 shares of common stock at $4.00 per share. The company's shares began trading on the Nasdaq Capital Market on February 5, 2025, under the ticker symbol 'CJMB'.
The company, which specializes in healthcare logistics and emergency management services, has granted underwriters a 45-day option to purchase up to an additional 192,000 shares. The net proceeds will be used for sales support, marketing, customer expansion and general corporate purposes, including working capital. Alexander Capital served as the managing underwriter and sole book runner, with Paulson Investment Company and Bancroft Capital acting as co-managers.
Callan JMB (NASDAQ: CJMB) has announced the pricing of its initial public offering of 1,280,000 shares at $4.00 per share, aiming to raise approximately $5.12 million in gross proceeds before deducting underwriting costs and offering expenses.
The company has granted underwriters a 45-day option to purchase up to an additional 192,000 shares at the public offering price. Trading is expected to begin on the Nasdaq Capital Market on February 5, 2025, under the ticker symbol 'CJMB', with the offering closing around February 6, 2025.
The net proceeds will be used for sales support, marketing, customer expansion, and general corporate purposes, including working capital. Alexander Capital is serving as the managing underwriter, with Paulson Investment Company as joint book-runner.